Investor: That is a good guess. I had the same thought - just not as quick as you. There’s science behind SR1 activation combatting the cytokine storm, inflammation, etc. However, Anavex does not have the resources to immediately pursue this. Anavex needs to remain focused on its pending clinical trials and its other day to day business. I imagine all of the available time of all of its employees is stretched as it is. Lastly, the material from this bio website does not have all of the typical securities language.
News 
Market Data 
Discover 
